drug development program News
-
Pronalyse Unveils Protein Drug Modification Analysis to Move Your Drug Development Program Forward
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. The company has recently announced Protein Drug Modification Analysis service to help researchers determine the modification type, modification site, and modification structure of protein drugs. Mature protein medicines have complete ...
-
MDA Venture Philanthropy Grant to Support Development of ALS Biomarkers
The Muscular Dystrophy Association is pleased to announce the award of an MDA Venture Philanthropy (MVP) grant totaling $233,200 to Scottsdale, Ariz.-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP ...
By nVector
-
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022. Dr. Haishan Jang, Chair and CEO ...
-
CD ComputaBio Unveils Ligand-based Pharmacophore Model Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the ...
-
Deep Genomics Raises $40 Million in Series B Financing
Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced ...
-
The importance of technical oversight (CMC) in drug development
The area of drug development is a veritable minefield with many junctures where a project can come to an abrupt end. The early discovery period presents its own significant challenges, but once a client has selected their lead candidate many organizations feel the heavy lifting is over, however this simply isn’t the case. The next steps of plotting out a clinical manufacturing process ...
By Biodextris
-
Groundbreaking new methodology published in Nature Medicine uncovers the missing numbers to the only clock that really matters in the body – your immune age
There is the age you say you are – which is not always accurate but always medically irrelevant. There is your chronological age – which is accurate but ignores inter-person variation. And then there is your immune age – the key determinant of future health and response to disease and treatment – quantified now for the first time, creating a potential paradigm shift ...
By CytoReason
-
VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates. “We are excited to expand our common mission and work with ...
By VeriSIM Life
-
Actym Therapeutics Announces Expansion of Scientific Advisory Board
BERKELEY, Calif., Jan. 13, 2021 /PRNewswire/ -- Actym Therapeutics Inc., a privately-held company focused on the development of immunotherapies to treat cancer from its attenuated, microbial-based STACT platform, announced today the appointments of Dr. Lawrence Fong, M.D. and Dr. Michel Streuli, Ph.D., to its Scientific Advisory Board (SAB). Actym's SAB comprises world-renowned subject matter ...
-
Eyevensys Announces Executive Leadership Team Expansion
Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the expansion of its leadership team with the appointment of Gerald Cagle as the ...
By Eyevensys
-
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from ...
-
Aerami Therapeutics Appoints Lisa Yanez as Chief Executive Officer
Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023. As part of a planned leadership transition, Steve Thornton will retire as CEO at the ...
-
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed ...
-
Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021. Atomwise was recognized for its unmatched AI platform, AtomNet®?, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most ...
-
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Over ...
-
Fluidda and Aptar Pharma Exclusive Collaboration
Fluidda, leader in the field of Functional Respiratory Imaging and developer of the medical device Broncholab®, today announced an exclusive collaboration with Nanopharm, an Aptar Pharma company and a leader in contract research and development services for orally inhaled and nasal drug products (OINDPs). The companies will leverage their respective proprietary technology platforms to help ...
By Fluidda
-
Bexson Biomedical Hires Veteran Medical Device Development Leader, Will Focus On New Dosing & Delivery Solutions For Controlled Substances
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its senior leadership team. As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable ...
-
Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...
-
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure ...
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you